SCHEMBL7717030

SCHEMBL7717030

CCOC(=O)CCCCP(=O)(O)OCC

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 1/20 0.52
CYP1A2 P05177 1/20 0.50
ENPP2 Q13822 6/20 0.43
LPAR3 Q9UBY5 4/20 0.43
LPAR1 Q92633 3/20 0.43
LPAR6 P43657 1/20 0.43
LPAR4 Q99677 1/20 0.43
LPAR5 Q9H1C0 1/20 0.43
LPAR2 Q9HBW0 1/20 0.43
ALDH1A1 P00352 1/20 0.42
CYP3A4 P08684 1/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
DGKA P23743 1/20 0.41
NR1I2 O75469 1/20 0.41
PGR P06401 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
PTGS2 P35354 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7718809 0.94 PPARD (0.53) PPARDCYP1A2ENPP2LPAR3LPAR1
SCHEMBL7716763 0.89 PPARD (0.55) PPARDCYP1A2ALDH1A1ALOX15TSHR
SCHEMBL4931741 0.85 CYP1A2 (0.50) PPARDCYP1A2ENPP2LPAR3LPAR1
SCHEMBL1406274 0.84 CYP1A2 (0.48) PPARDCYP1A2ENPP2LPAR3LPAR1
SCHEMBL8551385 0.84 CYP1A2 (0.48) PPARDCYP1A2ENPP2LPAR3LPAR1
SCHEMBL18590888 0.84 CYP1A2 (0.48) PPARDCYP1A2ENPP2LPAR3LPAR1
SCHEMBL4232740 0.84 CYP1A2 (0.48) PPARDCYP1A2ENPP2LPAR3LPAR1
SCHEMBL11372070 0.83 CYP1A2 (0.52) CYP1A2ENPP2LPAR3LPAR2ALDH1A1
SCHEMBL1060360 0.83 LPAR3 (0.52) CYP1A2ENPP2LPAR3LPAR1LPAR6
SCHEMBL11327789 0.82 DGKA (0.61) ENPP2LPAR3LPAR1LPAR6LPAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6376512-B1 FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-23 US disclosed
EP-0315399-B1 Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same RHONE POULENC RORER INT (US) 1996-01-10 EP disclosed
US-5059610-A QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1991-10-22 US disclosed
US-4920132-A Quinoline derivatives and use thereof as antagonists of leukotriene D4 RORER PHARMACEUTICAL CORP. (US) 1990-04-24 US disclosed